Hoffman S L, Berzofsky J A, Isenbarger D, Zeltser E, Majarian W R, Gross M, Ballou W R
Infectious Diseases Department, Naval Medical Research Institute, Bethesda, MD 20814-5055.
J Immunol. 1989 May 15;142(10):3581-4.
We conducted a series of experiments to define Ir gene regulation of the immune response to Plasmodium berghei sporozoites and circumsporozoite (CS) protein-derived subunit vaccines. The studies demonstrated that there is no apparent genetic restriction of the capacity to develop protective immunity against a large sporozoite challenge after immunization with irradiation-attenuated P. berghei sporozoites; that the Th response to (Asp-Pro-Ala-Pro-Pro-Asn-Ala-Asn)n, the predominant protective B epitope on the P. berghei CS protein, is genetically restricted and regulated by Class II genes (I-Ab) and by genes in the Class I region (H-2Dk) or telomeric to this region; and that this restriction can be overcome by immunization with a r protein including the entire P. berghei CS protein. The results support the development of full length human CS protein vaccines to take advantage of all potential T epitopes on this protein.
我们进行了一系列实验，以确定免疫反应相关基因（Ir基因）对伯氏疟原虫子孢子和环子孢子（CS）蛋白衍生亚单位疫苗的调控作用。研究表明，在用辐照减毒的伯氏疟原虫子孢子免疫后，针对大量子孢子攻击产生保护性免疫的能力没有明显的遗传限制；对伯氏疟原虫CS蛋白上主要的保护性B表位（Asp-Pro-Ala-Pro-Pro-Asn-Ala-Asn）n的Th反应受到遗传限制，并由II类基因（I-Ab）以及I类区域（H-2Dk）或该区域端粒处的基因调控；并且这种限制可以通过用包含完整伯氏疟原虫CS蛋白的重组蛋白免疫来克服。这些结果支持开发全长人CS蛋白疫苗，以利用该蛋白上所有潜在的T表位。
